Jeffrey W. Albers, Director: Blueprint Medicines BPMC Sell · Filed 24/12/20

Trade details

Type: Insider sale
Amount: $461,071.8
Shares · price: 5,180 sh · $89.01 a share
Held after: 163,457 sh
Stock: Blueprint Medicines BPMC
Person: Jeffrey W. AlbersDirector
Trade date: 24/12/19
Filed: 24/12/20
Days to filing: 1 days

Sold 3.1% of holdings

Share of holding sold: 3.1%

Blueprint Medicines trades, last 26 weeks

What else happened in Blueprint Medicines around then

Filed or reported within 30 days of the trade day · 24/11/19~25/01/18

Jeffrey W. Albers's recent trades

Jeffrey W. AlbersDirector
Planned sale10b5-1 planSpyre Therapeutics
Planned sale10b5-1 plan
Spyre Therapeutics
SYRE
$517.1K
5,000 sh
$517.1K
Filed 08/07
Traded 08/07
Jeffrey W. AlbersDirector
Planned sale10b5-1 planSpyre Therapeutics
Planned sale10b5-1 plan
Spyre Therapeutics
SYRE
$1.9M
18,000 sh
$1.9M
Filed 08/07
Traded 08/07
Jeffrey W. AlbersDirector
Sell10b5-1 planKymera Therapeutics
Sell10b5-1 plan
Kymera Therapeutics
KYMR
$245.5K
2,748 sh
$245.5K
Filed 25/12/08
Traded 25/12/08
Jeffrey W. AlbersDirector
Sell10b5-1 planKymera Therapeutics
Sell10b5-1 plan
Kymera Therapeutics
KYMR
$203.4K
2,252 sh
$203.4K
Filed 25/12/08
Traded 25/12/08
Jeffrey W. AlbersDirector
Planned sale10b5-1 planKymera Therapeutics
Planned sale10b5-1 plan
Kymera Therapeutics
KYMR
$333.1K
5,000 sh
$333.1K
Filed 25/12/08
Traded 25/12/08